Market revenue in 2023 | USD 3,292.5 million |
Market revenue in 2030 | USD 5,033.1 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Large molecules |
Fastest growing segment | Small molecules |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Large Molecules, Small molecules |
Key market players worldwide | Boehringer Ingelheim, Catalent Inc, Baxter International Inc, Eurofins Scientific SE, Recipharm, Fresenius SE & Co KGaA, Novartis AG ADR, Recro Pharma, Symbiosis Pharmaceutical Services, MabPlex International |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fill-finish pharmaceutical contract manufacturing market will help companies and investors design strategic landscapes.
Large molecules was the largest segment with a revenue share of 67.09% in 2023. Horizon Databook has segmented the Asia Pacific fill-finish pharmaceutical contract manufacturing market based on large molecules, small molecules covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific accounted for a revenue share of over 35.3% in 2022 in the fill-finish pharmaceutical contract manufacturing market. The market is driven by key factors, such as growing demand for pharmaceutical products, increasing outsourcing of pharmaceutical production, favorable government policies, and technological advancements.
For instance, in August 2021, Lonza added to the capacity at its biologics manufacturing facility in Guangzhou, China, by installing a new fill-finish line. Wages and material costs are lower in China and India, which drives the market for fill-finish pharmaceutical contract manufacturing.
The rapid expansion of the pharmaceutical industry is likely to be a major factor driving the demand for fill-finish manufacturing in the region. However, with increasing demand for products amid the COVID-19 pandemic, biopharmaceutical and pharmaceutical companies in countries such as India & China, which are the largest exporters to western companies, have increased their production of APIs.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific fill-finish pharmaceutical contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific fill-finish pharmaceutical contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account